Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In an important step for the endocrinology community, delegates at the 24th European Congress of Endocrinology in Milan, Italy, celebrated the first ever European Hormone Day and the launch of European Women in Endocrinology (EUWIN).
Sodium–glucose cotransporter 2 (SGLT2) inhibitor treatment affects central regulation of appetite and satiety, which results in increased carbohydrate intake. It has now been demonstrated that these effects might be blunted by combining SGLT2 inhibitors with glucagon-like peptide 1 receptor agonists to further facilitate weight loss in patients with type 2 diabetes mellitus.
This article discusses evidence for the emergence of a different set of complications associated with diabetes mellitus from the traditional ones, outlines the risks and burden of these associated complications and considers implications for the future management of diabetes mellitus.
Glucocorticoid therapies are widely used to treat acute and chronic inflammatory diseases, yet these drugs induce adverse metabolic effects. This Review highlights new insights into mechanisms of glucocorticoid-induced diabetes mellitus and discusses current and future therapeutic options.
The actions of growth hormone (GH) on growth and many other processes are well-described. This Review highlights clinical data from patients with acromegaly or GH deficiency, alongside data from cellular and animal studies, to reveal novel actions of GH in fibrosis, cardiovascular function and cancer.
This article discusses X chromosome agents of sexual differentiation. These agents could explain some of the sex differences in incidence and severity of particular diseases.
